Released on: September 17, 2008, 9:34 am

Press Release Author: Chris Hebel

Industry: Biotech

Press Release Summary: Several research groups have recently made discoveries of novel non-coding small RNAs. The small RNA discoveries were made possible, in part, by LC Sciences’ small RNA discovery service. The new microRNA sequences were included as part of the latest update to the miRBase sequence database of experimentally verified miRNAs. The Sanger Institute released the latest version (12.0) of miRBase on September 1st. The number of verified miRNAs has been increased from 6396 to 8619 hairpin precursor miRNAs expressing 8273 mature miRNA products. With the addition of 2062 new mature miRNA sequences, this represents the largest update in miRBase history.

Press Release Body: Non-coding (ncRNAs) are a large class of RNAs which do not encode proteins but possess regulatory functions at the level of translation in cells of various species. There are an increasing amount of data suggesting that there are likely many more ncRNAs that exist, yet to be discovered. Custom small RNA discovery microarrays have been shown to be an effective approach for uncovering novel ncRNAs experimentally1 and/or to validate predicted candidate ncRNAs2. Recently, researchers at Baylor College of Medicine employed a discovery strategy of computational prediction and microarray expression profiling to uncover a large number of novel small RNAs in embryonic stem (ES) cells3. Dr. Preethi Gunaratne and co-workers reported using computation, custom small RNA microarray from LC Sciences, and validation experiments to uncover hundreds of novel small RNAs in ES cells. These small non-coding RNAs (ncRNAs) were from adult tissue progenitor transcript sequences and are micro-conserved elements. The detection probes were designed for custom array synthesis by LC Sciences, Houston, TX and included the standard microRNA (miRNA) sequences in miRBase4, a comprehensive panel of 2,617 micro-conserved ncRNA sequences, and several hundreds of literature reported small RNAs or miRNAs. Two generations of custom array designs were used for optimizing the probes. These profiling studies using ES cell lines as well as normal adult mouse tissues identified 545 small RNAs that are enriched in ES cells over adult cells. Of these, more than 100 exhibited down-regulation in ES gene-knockout cells typical of miRNA.

In a similar way, LC Sciences’ custom small RNA arrays have provided means for validation of computational predictions of Bombyx mori (silkworm) 5 and Solanum lycopersicum (Tomato) 6 miRNAs. These are species whose genomes are incomplete at the present time. It is well known that miRNAs are important players for regulation of cellular activities. Therefore, the establishment of miRNAs in these traditional industrial or agricultural important species should lead to better understanding of the fundamentals of their growth, maturation, and disease-resistance.

The small RNA discoveries were made possible, in part, by LC Sciences’ small RNA discovery service. Using an innovative µParaflo® platform technology and proprietary probe design, it enables highly sensitive and specific direct detection of small RNAs in your sample. This service is comprehensive; from array design to sample to complete data set, allowing efficient and reliable discovery of novel miRNA and other types of ncRNAs.

The new Bombyx and Solanum sequences were included as part of the latest update to the miRBase sequence database of experimentally verified miRNAs. The Sanger Institute released the latest version (12.0) of miRBase on September 1st.

The number of verified miRNAs has been increased from 6396 to 8619 hairpin precursor miRNAs expressing 8273 mature miRNA products. With the addition of 2062 new mature miRNA sequences, this represents the largest update in miRBase history.

Many sequences have been updated or revised. For the first time, miRNAs are reported from: eleven new Drosophila species, Platypus, Tomato, Red Flour Bettle, and two Polyomaviruses. There has been a significant increase in the number of miRNAs reported for Human and model species such as Chimpanzee, Mouse, and Arabidopsis as well as agriculturally important species such as Rice, Soybean, Pig, and Chicken.

The updated probe content from miRBase version 12.0 is currently available on all of our standard or custom small RNA microarrays.

More information about LC Sciences’ Small Non-coding RNA Discovery Service and the µParaflo® technology is available at: http://www.lcsciences.com/small_non_coding.html.

About LC Sciences - LC Sciences is a genomics and proteomics products company offering a comprehensive line of DNA, RNA, and peptide microarrays for nucleic acid/protein profiling and functional analysis, biomarker-discovery, novel drug screening, and the custom development of miniaturized assay devices for diagnostics and biosensing applications. Based on the µParaflo® microfluidics technology, LC Sciences’ innovative products offer significant flexibility and customization capability for rapidly evolving, diverse customer needs. In an era of rapid technological advancement, LC Sciences offers service products which enable efficient one-stop solution for assays of DNA, RNA, protein, enzymes, antibodies, or small molecules. LC Sciences also provides unique synthetic DNA and RNA products such as OligoMix®, generated using their microfludic biochip synthesizer. These innovative products drive synthetic biology and systems biology applications by reducing the cost and increasing the speed of highly multiplexing large-scale nucleic acid and protein engineering experiments.

More information about LC Sciences is available at www.lcsciences.com.
1. Vagin VV, Sigova A, Li C, Seitz H, Gvozdev V, Zamore PD. (2006) A distinct small RNA pathway silences selfish genetic elements in the germline. Science 313(5785), 320-324.
2. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz L.A Jr, Sjoblom T, Barad O,
Bentwich Z, Szafranska AE, Labourier E, et al. (2006) The colorectal microRNAome. Proc Natl Acad Sci USA 103, 3687-92.
3. Gu P, Reid JG, Gao X, Shaw CA, Creighton C, Tran PL, Zhou X, Drabek RB, Steffen DL, Hoang DM, Weiss MK, Naghavi AO, El-daye J, Khan MF, Legge GB, Wheeler DA, Gibbs RA, Miller JN, Cooney AJ, Gunaratne PH. (2008) Novel MicroRNA Candidates and miRNA-mRNA Pairs in Embryonic Stem (ES) Cells. PloS One 3(7), e2548.
4. Griffiths-Jones S, Grocock R, van Dongen S, Bateman A, Enright A. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34 (Database issue), D140–D144.
5. He PA, Nie Z, Chen J, Chen J, Lv Z, Sheng Q, Zhou S, Gao X, Kong L, Wu X, Jin Y, Zhang Y. (2008) Identification and characteristics of microRNAs from Bombyx mori. BMC Genomics 9(1), 248.
6. Zhang J, Zeng R, Chen J, Liu X, Liao Q. (2008) Identification of conserved microRNAs and their targets from Solanum lycopersicum Mill. Gene [Epub ahead of print].

Web Site: http://www.lcsciences.com/small_non_coding.html

Contact Details: LC Sciences LLC
2575 West Bellfort Street, Suite 270
Houston, TX 77054
P-713-664-7087
F-713-664-8181
info@lcsciences.com

Released on: June 8, 2008, 2:37 pm

Press Release Author: Emo van Halsema/ HaloteC

Industry: Biotech

Press Release Summary: HaloteC proudly announces the launch of the new Alcohol Fermentation Monitor during the 24th Annual International Fuel Ethanol Workshop Expo on June 16-19, 2008 at the Gaylord Opryland Resort & Convention Center in Nashville, Tennessee.

Press Release Body: HaloteC launches new generation Alcohol Fermentation Monitor at the 24th Annual International Fuel Ethanol Workshop Expo

Zoetermeer, The Netherlands, June 9, 2008

During the past decade, HaloteC Instruments in The Netherlands has been at the forefront of developing new, high tech solutions for challenges encountered in the dynamic world of industrial biotechnology. An important development is the Alcohol Fermentation Monitor (AFM).

History
The development of this user-friendly and robust laboratory device started in 1998. The AFM has proven to be a valuable tool for companies and research institutes involved in bioethanol and potable alcohol production and general yeast research. With the current high market demand for easy to use, yet accurate screening devices for yeast and feedstock, HaloteC was devoted to the future of this machine and intensely enhanced the design and usability of the Alcohol Fermentation Monitor over the passed two years.

New Generation special features
The new generation AFM is capable of performing six anaerobic yeast fermentations simultaneously. Conversion rates and yields are accurately measured as a function of feedstock, yeast strains or other process conditions such as medium temperature. The control software makes it possible compare results and generate advanced performance indicator reports with a single mouse click.

Hardware
The AFM is constructed from robust stainless steel, is very easy to operate and clean and does not require any fermentation skills. Only standard laboratory glass-ware is used (250 ml or 500 ml flasks). Each of the six fermenter flasks can be started and stopped at any time; stirrer speeds and medium temperatures can be set or time programmed individually. The AFM is equipped with extremely strong magnetic stirrers, able to stir very viscous media such as lignocellulose hydrolysates that are commonly used for second generation bioethanol production.

Software
The AFM is entirely operated with straightforward PC software, which allows for controlling all six fermenter flasks, store and retrieve experimental data, perform advanced data analysis and generate Microsoft Excelв„ў reports instantly. The software has been designed intuitively and can be mastered within ten minutes.

Launch on US market
The new generation of the AFM will be introduced in the United States of America during the 24th Annual International Fuel Ethanol Workshop Expo on June 16-19 2008, at the Gaylord Opryland Resort & Convention Center in Nashville, Tennesee (booth 2308).

For more information, please contact:
Emo van Halsema, M.Sc.- Founder & CEO
T: +31(0)621 870 111
E: emo.van.halsema@halotec.com

HaloteC Instruments BV
Röntgenlaan 5a
NL-2719 DX Zoetermeer
The Netherlands
T: +31(0)79 3613 516
F: +31(0)79 3619 071
E: info@halotec.com

www.halotec.com

biofuel, fuel, oil , oilprice, oilprizes, petrol, ethanol, bioethanol, FEW

Web Site: http://www.halotec.com

Press Release Summary: LC Sciences announced today the publication of the 30th peer-reviewed study by one of its customers using the companyРІР‚в„ўs microarray service for analyzing microRNA expression profiles and for discovery of novel small RNAs. These studies, by leading researchers in the field, contribute to a fast growing body of knowledge defining this recently discovered class of regulatory RNAs.

Press Release Body: Houston, TX – February 27, 2008 – LC Sciences announced today the publication of the 30th peer-reviewed study by one of its customers using the company’s microarray service for analyzing microRNA expression profiles and for discovery of novel small RNAs. These studies, by leading researchers in the field, contribute to a fast growing body of knowledge defining this recently discovered class of regulatory RNAs.

LC SciencesРІР‚в„ў microRNA profiling service, powered by its Р’ВµParafloР’В® microfluidic technology, provides quick, reliable, fully analyzed data enabling researchers to immediately move forward with innovative research, and publish their results faster. Microarray results require extensive validation prior to publication and the speed with which researchers using this microRNA profiling service have published their discoveries demonstrates the high-quality and reliability of these results.

It has become clear that the simple idea that DNA makes RNA which makes protein is not a complete picture. We now know that RNA does much more than just make protein. Transcriptome microRNAs and other small RNAs found in non-coding regions of genomes, once considered unimportant, even “junk”, have been found to regulate the expression of genes acting in almost every area of biology. The publications to date by LC Sciences’ customers span a diverse range of study areas, including cancer research, neuroscience, cardiovascular research, reproductive biology, plant science, virology, stem cell research, endocrinology, and small RNA discovery.

The study of microRNA has attracted intense attention and one of the most exciting aspects of this field is many scientists are now thinking about just how much more we donРІР‚в„ўt know. Just as the regulatory functions of some of the known microRNAs are finally understood, many more microRNAs are just being discovered. The number of microRNA sequences in the public database (miRBase) has been increasing steadily as new microRNAs are experimentally verified and deposited there.

Especially in this rapidly evolving field, it is important for scientists to have access to the most up to date information and research tools. LC Sciences is giving researchers an edge through the use of their flexible Р’ВµParafloР’В® technology. On chip synthesis (vs. spotting) of the most up to date microRNA probes sequences from miRBase as well as addition of custom sequences is enabled through a unique combination of microfluidics, digital photolithography, and novel synthesis chemistry. This ensures that researchers have the most complete picture of microRNA expression in their samples and, through the use of completely custom microarrays, allows for discovery of novel small RNAs as well as validation of computationally predicted microRNAs. The Р’ВµParafloР’В® technologyРІР‚в„ўs exceptional sensitivity and specificity, and unique ability to stay current in this rapidly developing field has enabled groundbreaking research, as evidenced by the number of studies which have appeared in high impact journals, including Nature, Science, PNAS, Nucleic Acids Research, and RNA.

The 30th study, entitled “Endogenous human microRNAs that suppress breast cancer metastasis” appeared in the January 10th issue of Nature. Researchers at the Memorial Sloan-Kettering Cancer Center uncovered a set of microRNAs for which expression is specifically lost as human breast cancer cells develop metastatic potential. They further showed that restoring the expression of these microRNAs in malignant cells suppresses lung and bone metastasis by human cancer cells in vivo. The strong association of the loss of expression with metastatic relapse suggests the potential for the use of these molecules in prognostic stratification of breast cancer patients in addition to conventional clinical and pathological staging markers.

“We are very excited about the announcement of the 30th peer-viewed publication by one of our customers,” says Chris Hebel, Director of Business Development at LC Sciences. “This (microRNA) is turning into a very competitive area of research and scientists are racing to be the first to describe the mechanism of microRNA as it relates to their field of study. We’re finding that many researchers will send us samples that have no relation to any of the previously described microRNA regulated areas just to see if microRNA is involved in any way at all in their system. We’re happy to provide the first step into this exciting new field for them.”

About Р’ВµParafloР’В® Technology - The Р’ВµParafloР’В® technology is a microfluidic platform for in situ parallel synthesis of biomolecular chips and miniturization of bioassays including binding and enzymatic reactions. This unique platform technology is based on a new class of three-dimensional pico-liter microfluidic reaction devices, and a digital light controlled synthesis method that employs conventional oligonucleotide or peptide synthesis chemistry; a completely programmable process. The seamless integration of these multidisciplinary technologies enables a signifcant advance in parallelization, miniaturization, customization, and automation.

About LC Sciences - LC Sciences is a genomics and proteomics products company offering a comprehensive line of DNA, RNA, and peptide microarrays for nucleic acid/protein profiling and functional analysis, biomarker-discovery, novel drug screening, and the custom development of miniaturized assay devices for diagnostics and biosensing applications. Based on the Р’ВµParafloР’В® microfluidics technology, LC SciencesРІР‚в„ў innovative products offer significant flexibility and customization capability for rapidly evolving, diverse customer needs. In an era of rapid technological advancement, LC Sciences offers service products which enable efficient one-stop solution for assays of DNA, RNA, protein, enzymes, antibodies, or small molecules. LC Sciences also provides unique synthetic DNA and RNA products such as OligoMixР’В®, generated using their microfludic biochip synthesizer. These innovative products drive synthetic biology and systems biology applications by reducing the cost and increasing the speed of highly multiplexing large-scale nucleic acid and protein engineering experiments.

More information about LC Sciences is available at www.lcsciences.com.

1. Tavazoie SF, AlarcГіn C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, MassaguГ© J. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-52.

Web Site: http://www.lcsciences.com

Contact Details: 2575 West Bellfort Street
Suite 270
Houston, TX 77054
1-888-528-8818
FAX 713-664-8181
info@lcsciences.com

Press Release Summary: VisiGen Biotechnologies, Inc., was awarded US Patent No. 7,329,492, “Methods for Real-time Single Molecule Sequence Determination”, in addition to European and Australian counterparts.

Press Release Body: HOUSTON, TX – February 15, 2008 - VisiGen Biotechnologies, Inc., was awarded US Patent No. 7,329,492, “Methods for Real-time Single Molecule Sequence Determination”, European and Australian counterparts have also recently issued. VisiGen’s President, Dr. Susan Hardin, Ph.D. said, “We have the real path to the $1,000 human genome.” VisiGen’s sequencing methodology can be used to sequence the genome of a human or any other life form.

VisiGen’s DNA sequencing machines will enable low cost comprehensive genome analysis such as a one day, $1,000 human genome. VisiGen’s patented technology is scalable. VisiGen’s nanosequencing machines are designed to monitor massively parallel arrays to produce a DNA sequencing platform that will be capable of collecting DNA sequence data at the rate of 50 million bases per second or greater. VisiGen plans to offer a DNA sequencing service in late 2009 and to sell DNA sequencing machines and reagents 18 to 24 months later.

VisiGen has bioengineered polymerases and nucleotides to act together as direct molecular sensors of DNA sequence information during DNA replication. VisiGen’s novel platform uses single-molecule DNA detection, fluorescent molecule chemistry, computational biochemistry, and biomolecule engineering and purification. VisiGen’s method tags the terminal phosphate of a nucleotide with a fluorophore that is naturally released during nucleotide insertion into the growing DNA strand, thereby enabling a non-cyclical approach to DNA sequencing.

“We believe that our newly issued patent pre-dates certain other sequencing methodologies based on the use of terminal phosphate labeled nucleotides,” Dr. Hardin said, “so not only do we have to be mindful of the medical and pharmaceutical implications of our technology, but we must also be mindful of our own patent position in this fast developing field.”

About VisiGen Biotechnologies
VisiGen is a privately owned company located in Houston, Texas. VisiGen was founded in 2000 by the inventors of this revolutionary technology: Drs. Susan Hardin, Xiaolian Gao, Jim Briggs, Richard Willson, and Shiao-Chun (David) Tu. VisiGen is a spin-off from the University of Houston.

The company has received undisclosed investments from Applied Biosystems and SeqWright, and also is supported by grants from the Defense Advanced Research Projects Agency, the National Human Genome Research Institute, and the National Institute of General Medical Sciences.

VisiGen is a contender for the Archon X-Prize for Genomics, which will award a $10 million prize to the first entrant to sequence 100 human genomes in 10 days for no more than $10,000 per genome.

Web Site: http://visigenbio.com

Contact Details: Susan Hardin, Ph. D.
2575 West Bellfort, Suite 250
PHONE: 713-298-9325
FAX:713-665-9901
shardin@visigenbio.com

Press Release Summary: Imagine being able to detect breast and prostate cancer at it’s earliest stage, or even before it begins.

Press Release Body: ViroTech LLC announces its breakthrough cancer discovery…

ViroTech LLC announces its breakthrough discovery of the new HIV-like human cancer virus. The companyРІР‚в„ўs Vice President, Dr. Eva M. Rakowicz-Szulczynska has discovered and described this retrovirus several years ago but official classification of this new retrovirus was just recently approved by the National Center for Biotechnology Information. Genetic sequences and proteins of the virus were already deposited in the GenBank and are known in literature as Rakowicz (RAK) markers or RAK genes and RAK antigens. This novel virus is exogenous, and probably has derived from the same ancestor as HIV. ViroTech LLC has proved that the HIV-like human cancer virus stays invisible in the DNA of blood lymphocytes of many currently healthy people. When the new virus becomes active, it relocates to the reproductive organs, including breast, ovary, uterus, and vulva in women and prostate or testis in men, starting the process of malignant transformation. There are many known infectious cancer viruses in animals, and some viruses are also known to be associated with human cancers. However, in contrast to any other human viruses, which show only some links to cancer, this new HIV-like human cancer virus is present in 100% of breast, ovarian, uterine and prostate cancer cases, while it is completely absent in healthy tissues, and in the blood of non-infected individuals.

ViroTech LLC has developed and clinically tested a novel comprehensive diagnostic system, which allows detection of the gene RAK alpha of this HIV-like human cancer virus long before cancer develops. Inexpensive and non-invasive blood tests are developed by ViroTech LLC for the virus detection.

ViroTech LLC has also developed other diagnostic tests to monitor virus activation and relocation to specific organs. For example, detection of the viral DNA in the tissue biopsy can be monitored much earlier than cancer is detected by traditional pathological tests. New diagnostic tests would allow starting therapy even before cancer develops. In the future, peptide vaccines and DNA vaccines would be developed for cancer prevention.

ViroTech LLC has successfully completed pre-clinical and clinical evaluation of its proprietary diagnostic tests in the USA and Europe, while using over 4000 volunteers. With NCBI-GenBank official classification of this novel lentivirus, ViroTech LLC expects to get expedited regulatory approvals from the Food and Drug Administration. The final confirmatory trials for the first breast cancer test kit have to be performed under FDA supervision in three independent US cancer centers with 200 patients per center, giving a total of 600 altogether. ViroTech LLC expects to complete the first part of the trials within eight months and the final part within a few months later. Assuming funding is raised early in 2008, final approval by the FDA is expected by the end of the last quarter of 2009, with sales beginning in mid 2010.

The company has protected its core intellectual property by means of a number of key patents. These allow the company to exclusively utilize MAb RAK BrI, as well as also protect a number of other key compounds.

There is little direct competition to ViroTech LLC in terms of its technology, rather ViroTech LLC is competing against existing techniques. ViroTech LLCРІР‚в„ўs approach is cheaper and more accurate than current approaches, such as mammograms. In addition, ViroTech LLCРІР‚в„ўs technology is the only one which allows detecting pre-cancerous changes occurring in reproductive organs of the currently healthy people.

Substantial equity in the company is available through a private stock offering and multibillion dollar markets should be anticipated. ViroTech LLC is currently reviewing sites in Daytona Beach, Florida for a new research Laboratory to continue work on this amazing discovery.

Web Site: http://virotech.us

Contact Details: James M Sleighter
Health Food Hut Inc
1024 North Atlantic Ave
Daytona Beach, Florida 32117
http://www.healthfoodhut.com
imasters@tampabay.rr.com
(352) 201-2536
Your health is your biggest asset……

Press Release Summary: Upper management of small- to mid-size biotech companies now have a knowledgeable resource to assist with their sales and marketing. If you would like to jump-start your revenue, Axcela Consulting can supply innovative ways to sell your products and services to your target market.

Press Release Body: Tempe, AZ – January 21, 2008 – Upper management of small- to mid-size biotech companies now have a knowledgeable resource to assist with their sales and marketing. If you would like to jump-start your revenue, Axcela Consulting can supply innovative ways to sell your products and services to your target market.

Stacey Stewart, Ph.D., founder of Axcela Consulting, is well-prepared to understand the business and technical segments of your company; her credentials include over 16 combined years of molecular biology research, biotech field sales and sales management experience. With the assistance of Axcela Consulting, biotech companies can draw on the talent of a highly trained and successful sales professional without the long-term expense and commitment of hiring a full-time employee. Axcela Consulting provides a responsive and focused approach dedicated specifically to the needs of small- to mid-size biotech companies, making their services unique.

According to Dr. Stewart, “I saw the need for this type of consulting firm after many years of working with biotech companies. It became clear to me that these growing companies could strongly benefit from the input of a sales professional but didn’t have the resources to hire highly-experienced staff. I view my services as being a ‘time-share’ for biotech companies that recognize the need to make their marketing and sales a priority.”

After earning her Ph.D. in Biological Sciences at the University of California, Irvine, Dr. Stewart became a Field Applications Specialist for Promega Corporation with technical support and sales responsibilities for the Northwest U.S. and British Columbia. She was later promoted to Western Regional Manager for Promega, with nine direct reports covering the Western U.S. and the entire Canadian market. During her tenure at Promega, she was promoted twice and received nine awards for sales accomplishments.

Important aspects of the responsive and collaborative services at Axcela Consulting are the no-charge initial consultation and project proposal. Included in the project proposal are a variety of options to reach the agreed-upon goals of the project, each associated with a flat fee so that the client has a clear idea of the cost before the project onset. A white paper that discusses why some biotech companies use consultants and what to consider when seeking a consultant is available at http://www.axcelaconsulting.com/index.php?option=com.

Web Site: http://www.axcelaconsulting.com

Contact Details: http://www.axcelaconsulting.com
Stacey Stewart, Ph.D.
stacey@axcelaconsulting.com
Phone: 480-993-2398
Fax: 888-870-9229

Press Release Summary: Patients suffering from a range of debilitating illnesses, such as spinal cord injury, cerebral palsy, optic nerve hypoplasia, multiple sclerosis and ataxia stand to benefit from a new laboratory, established with a Chinese Government grant. Such a facility will put China at the forefront of the global race to engineer and reprogram human stem cells for positive medical benefit.

Press Release Body: November 7, 2007 - SHENZHEN, China – Beike Biotechnology, (http://www.beikebiotech.com), the leader in stem cell applications for medical treatment, has announced that it has formally established a world-class laboratory facility for the research of cell reprogramming and gene engineering, through a joint agreement with the Shenzhen Graduate School of China’s renowned Tsinghua University. The lab will conduct research on stem cells, the nuclear transfer and reprogramming of cells, monoclonal antibodies known as “magic bullets” for treating disease and other scientifically exciting cell engineering innovations. The aim of the lab is to establish a global research hub that will hopefully someday provide breakthroughs in the way medical science seeks to treat diseases like cancer, Parkinson’s, and many other debilitating ailments.

“We are already helping thousands of patients with our current umbilical cord stem cell treatments, but this ultra high-tech lab will bring us even closer to our goal of helping millions of patients improve their quality of life and will ensure that we have more advanced products in our pipeline four to five years out.” said Beike Biotech’s Chairman, Dr. Sean Hu. Detailed patient experiences with videos of patients that have been treated with Beike’s umbilical cord treatment can be found on China’s stem cell news website: http://www.stemcellschina.com.

The 1,200 square meter laboratory will be housed in Beijing-based Tsinghua University’s special Shenzhen Graduate Campus located in this southern Chinese city that borders Hong Kong. Building on Beike’s years of experience in successfully using stem cells to treat humans with serious brain and nerve maladies, this designated “China Key Laboratory” marks the country’s entry into the current global race to find new stem cell therapies that can be applied medically. The USD $4 million grant will be spent purely on equipment and comes from the Shenzhen Municipal Government as part of a US$12 million grant given out in 2007 to encourage innovative technologies in Shenzhen.

Further grants from the government are expected to help cover the cost of running the lab and expansion. The lab is to be staffed by over 50 people, including 20 renowned Chinese Phd’s and well-known researchers like Dr. Zhang Hai, who has published articles widely in Western periodicals, for example, “Nature” of her breakthroughs in research of microRNA and other cell building blocks.

“Dr. Zhang Hai is a pioneer and our work with her will allow Beike to lead the world not only in clinical applications of stem cells but also in basic research. Outside of China, it is not easy to get a 20 Phd’s together in a first class lab focusing on stem cell research. We expect to have some breakthroughs come out of this and more publications in leading journals,” Dr. Sean Hu said.

Stem cells are the master cells that replenish all the body’s tissues, from skin and blood to the brain and heart. They have proven capability to assist in nerve and organ regeneration, enable tissue repair and restoration, and are even thought to be able to effectively treat cardiovascular diseases and cancer. Beike currently has seen significant success using stem cells to treat a variety of nervous system disorders for Chinese and International patients alike. (Details can be found at http://www.stemcellschina.com). Many of these conditions are still deemed untreatable using conventional medical techniques and account for an estimated 60% of gross mortality worldwide. While not currently possible, scientists in labs like the one being established in Shenzhen are narrowing in on the technology that may soon allow for the reprogramming of human body cells. This would allow for the potential to regenerate nerve cells to heal spinal cord injuries, create oneРІР‚в„ўs own pancreatic cells to stop diabetes, or possibly generate cells of any other tissue type to treat whatever ails patients. This makes the successful application of stem cells of vital significance to human health and the medical field.

About Beike Biotechnology Company Limited

Beike is a biotechnology company that was founded in July 2005 with capital from Beijing University, Hong Kong University of Science and Technology and Shenzhen City Hall when it commercialized stem cell technology that had been in research since 1999. As a private high-tech enterprise, it is dedicated to the clinical application of stem cell research. It is also supported with funds from the China State National Fund. The research and clinical work is a collaboration of Beijing University, Hong Kong University of Science and Technology, No. 3 Army Medical University, Zhongshan Medical University, Guiyang Medical College and Zhengzhou University.

About The Graduate School at Shenzhen, Tsinghua University

The Graduate School of Tsinghua University in Shenzhen is an institute jointly established by Shenzhen City Hall and Tsinghua University to provide training for talent at the postgraduate level in science and technical innovation. As the only non-Beijing located educational facility run by Tsinghua University, the Graduate School of Tshinghua in Shenzhen is committed to the integration of teaching, research, and rapid commercialization of scientific discovery.

For more information, please contact:
Jonathan Hakim
Beike Biotech Company, Ltd.
Shenzhen Hi-Tech Industrial Park
info@beikebiotech.com
http://www.beikebiotech.com

Web Site: http://www.stemcellguidance.com

Contact Details: Jai Communications
MBE#056, 3rd Fl, Silom Complex, 191 Silom Road, Bangrak, Bangkok, 10500, Thailand
Ph:+66819878197
Email:Jai.Communications@gmail.com

Released on: October 17, 2007, 12:48 pm

Press Release Author: Burton Lee

Industry: Biotech

Press Release Summary: Human Prostate Specific Antigen for Cancer Research

Press Release Body: Saint Louis, MO Lee Biosolutions (www.leebio.com) now has available the highest quality Human Prostate Specific Antigen (PSA) and prostatic acid phosphatase enzyme (PAP) for research and bulk quantities for the clinical diagnostic manufacturer.

Current Immunohistochemical studies have shown that human Prostate Specific Antigen is confined to the cytoplasm of prostatic acinar cells and ductal epithelium. Human Prostate Specific Antigen PSA is present in normal, benign hyperplastic and malignant prostatic tissue, in mestatic prostatic carcinoma and also prostatic fluid and seminal plasma.

Human tumor marker Prostate Specific Antigen (PSA) is present in small quantities in the serum of normal men, and is often elevated in the presence of prostate cancer and in other prostate disorders.

Lee Biosolutions isolates both human prostatic acid phosphatase and human prostate specific antigen from our semen donors.

Human Prostate Acid Phosphatase also known as human prostatic acid phosphatase (PAP,ACP) is alternative marker to prostate specific antigen (PSA) for prostate malignancy. Rape investigations will often include testing for the presence of Human prostatic acid phosphatase in vaginal fluid.

Human prostatic Acid phosphatase (PAP) is a phosphatase, a type of enzyme, used to free attached phosphate groups from other molecules during digestion.

“Lee Biosolutions has developed a reputation for high-quality biomarker production,” said Lee. “As a manufacturer of high purity human enzymes and related proteins, we are able to custom fill orders and we will, likewise, place the protein in the buffer of your choice, if required.”

Lee Biosolutions is a leader in the biomaterials industry, providing quality proteins to clinical labs and researchers around the world, developing tomorrowРІР‚в„ўs cures. The company has provided proteins in a number of high profile biomarker studies.

Web Site: http://www.leebio.com

Contact Details: Burton Lee
President
Lee Biosolutions, Inc
2924 Mary Ave
St. Louis, MO 63144
314-968-1091

Released on: September 29, 2007, 8:40 am

Press Release Author: James A. Margrave / Dot Anderson

Industry: Biotech

Press Release Summary: Canton, TX - September 28th, 2007 - Snooztime, Inc. announces the introduction of the Pink Ribbon pillow to be sold at the TX St Fair and online. Snooztime pledges 100% of profits to Cancer Charities. Extraordinary comfort is one of the primary benefits to patients who have had a Mastectomy or Lumpectomy.

Press Release Body: Ask someone what goes on in Texas in October and theyРІР‚в„ўll likely say the Texas State Fair or National Breast Cancer Awareness Month. Snooztime, Inc., a manufacturer of microbead pillows will utilize their booth in the Grand Place Exhibit Building to introduce fair goers to their Pink Ribbon mini pillows and teddy bears and will donate 100% of the profits from these items sold at the fair to cancer charities.

“Hundreds, if not thousands of companies offer pink or pink ribbon products that support breast cancer research, but most of these products don’t offer a direct benefit to the breast cancer patient,” said Donna Harmon, president and co-founder of Snooztime. “Our microbead mini pillows are the perfect size for providing special support to cancer patients following mastectomies and lumpectomies and our baby bears are comforting.”

“Through response from our customers, we realized there was a far greater use for microbead pillows than we ever imagined,” added Harmon. “When we found out that many mastectomy patients were using our mini pillows, we decided to introduce them with a cheerful pink ribbon covering. Our goal is to bring extra comfort to breast cancer patients as well as raise awareness for breast cancer and help provide financial support for cancer charities.”

Microbead pillows are the newest innovation in pillow technology. Unlike memory foam pillows, microbead filled pillows instantly adjust to head, neck and body shape. This means that during sleep, the microbead pillow continuously changes and adapts to reduce or equalize pressure so that the head and neck or body area is comfortably supported.

Snooztime pillows use denatured, food grade, closed cell micro beads, which are small, smooth and nonabsorbent. Because the beads are spherical, they always maintain small airflow gaps between each one. This allows for positive airflow throughout the pillow, which disperses heat making the pillow cooler and more comfortable. SnooztimeРІР‚в„ўs microbead pillows are also naturally hypoallergenic and resist the growth of mold, mildew and bacteria. They are completely machine washable.

This area company makes a complete line of microbead pillows including personal and mini size roll pillows, U-shaped pills for the neck, personal size flat travel pillows, full size bed pillows and body pillows. The company also makes pet pillows and ultra soft teddy bears.

About Snooztime, Inc.
Snooztime, Inc, is a small family-owned business founded in 2004 by David and Donna Harmon. Based in Canton, TX, the company manufactures a complete line of microbead pillows including full size luxury bed and body pillows, personal and travel size pillows, and pet pillows. The company was founded on business principals that include tradition, integrity and family values. Snooztime, offers a 30-day risk free trial of their products.

Web Site: http://www.snooztime.com/pink_ribbon.php

Contact Details: Snooztime, Inc.
231 VZCR 4104
Canton, TX 75103

Contact:
James A. Margrave
Operations Manager
903-567-5258 Office
903-567-4698 Fax
james@snooztime.com